Literature DB >> 18434750

Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance.

Krista Karstila1, Aimo P T Harmoinen, Terho J Lehtimäki, Markku M Korpela, Jukka T Mustonen, Heikki H T Saha.   

Abstract

BACKGROUND/AIM: Knowledge of the usefulness of cystatin C measurement in the detection of chronic kidney disease in patients with rheumatoid arthritis (RA) is scant. The purpose of this study was to evaluate the ability of plasma cystatin C- and creatinine-based methods to predict glomerular filtration rate (GFR) and classify chronic kidney disease in RA patients.
METHODS: The study population consisted of 64 RA patients aged 41-86 years. Comparisons were made between measured plasma creatinine, cystatin C, creatinine clearance and GFR estimated by the Cockcroft-Gault (CG) and the Modification of Diet in Renal Disease (MDRD) formulas. The plasma clearance of (51)Cr-EDTA served as a reference.
RESULTS: The Pearson correlation coefficients between plasma clearance of (51)Cr-EDTA and the markers of GFR were calculated. The correlation coefficients were 0.800 for plasma creatinine, 0.863 for cystatin C, 0.866 and 0.904 for GFR values estimated by MDRD and CG and 0.922 for plasma creatinine clearance. Statistically significant differences were detected between the correlation coefficients of plasma creatinine and GFR estimated by CG (p = 0.0412) and plasma creatinine and creatinine clearance (p = 0.0099). Creatinine clearance and the MDRD and CG formulas proved to be better at identifying GFR <90 ml/min than plasma creatinine or cystatin C.
CONCLUSION: We recommend using the CG formula or creatinine clearance for the estimation of the GFR of RA patients instead of solely creatinine or cystatin C in clinical work. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434750     DOI: 10.1159/000127362

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  5 in total

1.  Serum cystatin C level in patients with rheumatoid arthritis after single infusion of infliximab.

Authors:  M Kopec-Medrek; M Widuchowska; A Kotulska; E Zycinska-Dębska; E J Kucharz
Journal:  Rheumatol Int       Date:  2010-07-25       Impact factor: 2.631

Review 2.  Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review.

Authors:  Willemijn L Eppenga; Cornelis Kramers; Hieronymus J Derijks; Michel Wensing; Jack F M Wetzels; Peter A G M De Smet
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

3.  Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.

Authors:  Joel M Kremer; Alan J Kivitz; Jesus A Simon-Campos; Evgeny L Nasonov; Hans-Peter Tony; Soo-Kon Lee; Bonnie Vlahos; Constance Hammond; Jack Bukowski; Huihua Li; Seth L Schulman; Susan Raber; Andrea Zuckerman; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2015-04-06       Impact factor: 5.156

4.  Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.

Authors:  John D Isaacs; Andrea Zuckerman; Sriram Krishnaswami; Chudy Nduaka; Shuping Lan; Matthew M Hutmacher; Mary G Boy; Ken Kowalski; Sujatha Menon; Richard Riese
Journal:  Arthritis Res Ther       Date:  2014-07-25       Impact factor: 5.156

5.  Serum cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment.

Authors:  Jung-Yoon Choe; Sung-Hoon Park; Seong-Kyu Kim
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.